[Adaptol--verges of possible].<\/title><secondary-title>Likars'ka sprava<\/secondary-title><\/titles><dates><year>2012<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>2<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Vorob'eva OV<\/author><author>Rusaya VV<\/author><\/authors><\/contributors><titles><title>[Pharmacotherapy of anxiety disorders in patients with chronic cerebral ischemia].<\/title><secondary-title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova<\/secondary-title><\/titles><dates><year>2016<\/year><\/dates><electronic-resource-num>10.17116\/jnevro201611612249-54<\/electronic-resource-num><urls><related-urls><url>https:\/\/doi.org\/10.17116\/jnevro201611612249-54<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>3<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Zhitkova JV<\/author><author>Hasanova DR<\/author><\/authors><\/contributors><titles><title>[An experience of using mebicar in patients with autonomic dysfunction associated with anxiety disorder].<\/title><secondary-title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova<\/secondary-title><\/titles><dates><year>2017<\/year><\/dates><electronic-resource-num>10.17116\/jnevro201711711156-63<\/electronic-resource-num><urls><related-urls><url>https:\/\/doi.org\/10.17116\/jnevro201711711156-63<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>4<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Orlov EV<\/author><author>Konnov PE<\/author><author>Arsen'eva AA<\/author><\/authors><\/contributors><titles><title>[Clinical efficiency of combined therapy using adaptol for atopic dermatitis].<\/title><secondary-title>Terapevticheskii arkhiv<\/secondary-title><\/titles><dates><year>2014<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>5<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Serov NV<\/author><author>Treskov VG<\/author><author>Berliand AS et al.<\/author><\/authors><\/contributors><titles><title>[Clinical pharmacokinetics of mebikar].<\/title><secondary-title>Farmakologiia i toksikologiia<\/secondary-title><\/titles><dates><year>1984<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>6<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Kim CY<\/author><author>Kim YG<\/author><author>Sin SJ et al.<\/author><\/authors><\/contributors><titles><title>Preventive Effect of Mebicar and Ginsenoside Rg1 on Neurobehavioral and Immunological Disruptions Caused by Intermittent Unpredictable Stress in Mice.<\/title><secondary-title>Neuroimmunomodulation<\/secondary-title><\/titles><dates><year>2018<\/year><\/dates><electronic-resource-num>10.1159\/000489634<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>7<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Chutko LS<\/author><author>Surushkina SIu<\/author><author>Nikishena IS et al.<\/author><\/authors><\/contributors><titles><title>[Adaptol in the treatment of ADHD].<\/title><secondary-title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova<\/secondary-title><\/titles><dates><year>2009<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>8<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Kazakov YM<\/author><author>Potiazhenko MM<\/author><author>Nastroga TV<\/author><\/authors><\/contributors><titles><title>TREATMENT OPTIMIZATION IN MANAGEMENT OF COMBINED PATHOLOGY - ARTERIAL HYPERTENSION AND POST-COVID SYNDROME IN ELDERLY PATIENTS.<\/title><secondary-title>Wiadomosci lekarskie (Warsaw, Poland : 1960)<\/secondary-title><\/titles><dates><year>2023<\/year><\/dates><electronic-resource-num>10.36740\/WLek202307105<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>9<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Chutko LS<\/author><author>Surushkina SI<\/author><author>Nikishena IS et al.<\/author><\/authors><\/contributors><titles><title>[Asthenic disorders in children and their differentiated treatment].<\/title><secondary-title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova<\/secondary-title><\/titles><dates><year>2014<\/year><\/dates><electronic-resource-num>10.17116\/jnevro201411412199-103<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>10<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Kuz'menko VV<\/author><author>Kuz'menko AV<\/author><author>Kurnosova NV<\/author><\/authors><\/contributors><titles><title>[Correction of psychoemotional status in patients with chronic bacterial prostatitis].<\/title><secondary-title>Terapevticheskii arkhiv<\/secondary-title><\/titles><dates><year>2012<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>11<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Kamburg RA<\/author><author>Zaikonnikova IV<\/author><\/authors><\/contributors><titles><title>[Results of the experimental study and clinical use of the tranquilizer mebikar].<\/title><secondary-title>Farmakologiia i toksikologiia<\/secondary-title><\/titles><dates><year>1986<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>12<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Kirshin SV<\/author><author>Zimakova IE<\/author><\/authors><\/contributors><titles><title>[GABA-ergic component in the action of the tranquilizing agent mebikar].<\/title><secondary-title>Farmakologiia i toksikologiia<\/secondary-title><\/titles><dates><year>1982<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>13<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Chutko LS<\/author><author>Surushkina SY<\/author><author>Anisimova TI<\/author><\/authors><\/contributors><titles><title>[A dyad approach to the treatment of attention deficit hyperactivity disorder].<\/title><secondary-title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova<\/secondary-title><\/titles><dates><year>2017<\/year><\/dates><electronic-resource-num>10.17116\/jnevro20171172181-84<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>14<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Zimakova IE<\/author><author>Kirshin SV<\/author><author>Kamburg RA<\/author><\/authors><\/contributors><titles><title>[Comparative analysis of the behavioral, neurochemical and autonomotropic effects of mebikar and diazepam].<\/title><secondary-title>Farmakologiia i toksikologiia<\/secondary-title><\/titles><dates><year>1982<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>15<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Vorob'eva OV<\/author><author>Repina VV<\/author><\/authors><\/contributors><titles><title>[An open comparative observational study of the efficacy and safety of adaptol in anxiety-asthenic disorders in patients with chronic cerebral ischemia].<\/title><secondary-title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova<\/secondary-title><\/titles><dates><year>2016<\/year><\/dates><electronic-resource-num>10.17116\/jnevro20161163120-24<\/electronic-resource-num><\/record>\n<\/records><\/xml>\n"

"\n\nMolGod<\/database>MOL-GOD<\/source-app>1<\/rec-number>17<\/ref-type>Mkrtchian VR<\/author>Kozhokova LZ<\/author><\/authors><\/contributors>[Adaptol--verges of possible].<\/title><secondary-title>Likars'ka sprava<\/secondary-title><\/titles><dates><year>2012<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>2<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Vorob'eva OV<\/author><author>Rusaya VV<\/author><\/authors><\/contributors><titles><title>[Pharmacotherapy of anxiety disorders in patients with chronic cerebral ischemia].<\/title><secondary-title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova<\/secondary-title><\/titles><dates><year>2016<\/year><\/dates><electronic-resource-num>10.17116\/jnevro201611612249-54<\/electronic-resource-num><urls><related-urls><url>https:\/\/doi.org\/10.17116\/jnevro201611612249-54<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>3<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Zhitkova JV<\/author><author>Hasanova DR<\/author><\/authors><\/contributors><titles><title>[An experience of using mebicar in patients with autonomic dysfunction associated with anxiety disorder].<\/title><secondary-title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova<\/secondary-title><\/titles><dates><year>2017<\/year><\/dates><electronic-resource-num>10.17116\/jnevro201711711156-63<\/electronic-resource-num><urls><related-urls><url>https:\/\/doi.org\/10.17116\/jnevro201711711156-63<\/url><\/related-urls><\/urls><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>4<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Orlov EV<\/author><author>Konnov PE<\/author><author>Arsen'eva AA<\/author><\/authors><\/contributors><titles><title>[Clinical efficiency of combined therapy using adaptol for atopic dermatitis].<\/title><secondary-title>Terapevticheskii arkhiv<\/secondary-title><\/titles><dates><year>2014<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>5<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Serov NV<\/author><author>Treskov VG<\/author><author>Berliand AS et al.<\/author><\/authors><\/contributors><titles><title>[Clinical pharmacokinetics of mebikar].<\/title><secondary-title>Farmakologiia i toksikologiia<\/secondary-title><\/titles><dates><year>1984<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>6<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Kim CY<\/author><author>Kim YG<\/author><author>Sin SJ et al.<\/author><\/authors><\/contributors><titles><title>Preventive Effect of Mebicar and Ginsenoside Rg1 on Neurobehavioral and Immunological Disruptions Caused by Intermittent Unpredictable Stress in Mice.<\/title><secondary-title>Neuroimmunomodulation<\/secondary-title><\/titles><dates><year>2018<\/year><\/dates><electronic-resource-num>10.1159\/000489634<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>7<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Chutko LS<\/author><author>Surushkina SIu<\/author><author>Nikishena IS et al.<\/author><\/authors><\/contributors><titles><title>[Adaptol in the treatment of ADHD].<\/title><secondary-title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova<\/secondary-title><\/titles><dates><year>2009<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>8<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Kazakov YM<\/author><author>Potiazhenko MM<\/author><author>Nastroga TV<\/author><\/authors><\/contributors><titles><title>TREATMENT OPTIMIZATION IN MANAGEMENT OF COMBINED PATHOLOGY - ARTERIAL HYPERTENSION AND POST-COVID SYNDROME IN ELDERLY PATIENTS.<\/title><secondary-title>Wiadomosci lekarskie (Warsaw, Poland : 1960)<\/secondary-title><\/titles><dates><year>2023<\/year><\/dates><electronic-resource-num>10.36740\/WLek202307105<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>9<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Chutko LS<\/author><author>Surushkina SI<\/author><author>Nikishena IS et al.<\/author><\/authors><\/contributors><titles><title>[Asthenic disorders in children and their differentiated treatment].<\/title><secondary-title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova<\/secondary-title><\/titles><dates><year>2014<\/year><\/dates><electronic-resource-num>10.17116\/jnevro201411412199-103<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>10<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Kuz'menko VV<\/author><author>Kuz'menko AV<\/author><author>Kurnosova NV<\/author><\/authors><\/contributors><titles><title>[Correction of psychoemotional status in patients with chronic bacterial prostatitis].<\/title><secondary-title>Terapevticheskii arkhiv<\/secondary-title><\/titles><dates><year>2012<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>11<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Kamburg RA<\/author><author>Zaikonnikova IV<\/author><\/authors><\/contributors><titles><title>[Results of the experimental study and clinical use of the tranquilizer mebikar].<\/title><secondary-title>Farmakologiia i toksikologiia<\/secondary-title><\/titles><dates><year>1986<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>12<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Kirshin SV<\/author><author>Zimakova IE<\/author><\/authors><\/contributors><titles><title>[GABA-ergic component in the action of the tranquilizing agent mebikar].<\/title><secondary-title>Farmakologiia i toksikologiia<\/secondary-title><\/titles><dates><year>1982<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>13<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Chutko LS<\/author><author>Surushkina SY<\/author><author>Anisimova TI<\/author><\/authors><\/contributors><titles><title>[A dyad approach to the treatment of attention deficit hyperactivity disorder].<\/title><secondary-title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova<\/secondary-title><\/titles><dates><year>2017<\/year><\/dates><electronic-resource-num>10.17116\/jnevro20171172181-84<\/electronic-resource-num><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>14<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Zimakova IE<\/author><author>Kirshin SV<\/author><author>Kamburg RA<\/author><\/authors><\/contributors><titles><title>[Comparative analysis of the behavioral, neurochemical and autonomotropic effects of mebikar and diazepam].<\/title><secondary-title>Farmakologiia i toksikologiia<\/secondary-title><\/titles><dates><year>1982<\/year><\/dates><\/record>\n<record><database name=\"MolGod\">MolGod<\/database><source-app name=\"MOL-GOD\" version=\"3.1.4\">MOL-GOD<\/source-app><rec-number>15<\/rec-number><ref-type name=\"Journal Article\">17<\/ref-type><contributors><authors><author>Vorob'eva OV<\/author><author>Repina VV<\/author><\/authors><\/contributors><titles><title>[An open comparative observational study of the efficacy and safety of adaptol in anxiety-asthenic disorders in patients with chronic cerebral ischemia].<\/title><secondary-title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova<\/secondary-title><\/titles><dates><year>2016<\/year><\/dates><electronic-resource-num>10.17116\/jnevro20161163120-24<\/electronic-resource-num><\/record>\n<\/records><\/xml>\n"